Contract research, development and manufacturing organisation (CRDMO) BioDuro has entered into a partnership with small molecule design technology specialist, Silicogenix.
Through this partnership, BioDuro will combine its drug discovery platform with SGX's novel frameworks, aiming to lower the cost and time barriers associated with the development of complex therapies.
Silicogenix's technology allows biopharma companies to rapidly test new therapies — including possible combinations with standard-of-care treatments.
It is able to achieve this since the technology has access to the majority of the human proteome.
By combining this with BioDuro's drug discovery platform, the companies can assist the development of various complex molecules at speed.
The combination also reduces the cost of progression from discovery to preclinical development, according to the companies.
“We are focused on the continued innovation of our fully integrated services to help meet growing demand for early drug discovery," said Dr. Subas Sakya, Chief Scientific Officer at BioDuro.
“We are excited to partner with SGX to enable an alternative path for new drug discovery, propelling first-in-class therapeutics with the potential to save lives.”
“This is a pivotal moment for the biopharmaceutical industry, and this partnership is a significant step forward for how novel treatments for complex and rare diseases can be quickly brought to market,” said Dr. Shailesh Date, Co-founder of Silicogenix.
“BioDuro is an undisputed leader and we believe our collective approach will help biopharmaceutical companies greatly expedite the development cycle for therapeutics that address unmet medical needs.”